Harpoon Therapeutics, Inc. (HARP) is a publicly traded company in the Unknown sector. Across all available filings, 32 corporate insiders have executed 268 transactions totaling $616.9M, demonstrating a bullish sentiment with $487.0M in net insider flow. The most recent transaction on Mar 11, 2024 involved a purchase of 21,397,205 shares valued at $492.1M.
No significant insider buying has been recorded for HARP in the recent period.
No significant insider selling has been recorded for HARP in the recent period.
Based on recent SEC filings, insider sentiment for HARP is bullish with an Insider Alignment Score of 89/100 and a net flow of $487.0M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Harpoon Therapeutics, Inc. (HARP) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 32 insiders are actively trading HARP stock, having executed 268 transactions in the past 90 days. The most active insider is &. Co., Inc. Merck (Executive), who has made 1 transactions totaling $492.1M.
Get notified when executives and directors at HARP file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Mar 11, 2024 | Co., Inc. Merck &. | Executive | Purchase | 21,397,205 | $23.00 | $492.1M | Large |
| Mar 11, 2024 | S. Bailes Joseph | Executive | Disposition | 5,000 | $N/A | $0 | |
| Mar 11, 2024 | Marie Eastland Julia | Executive | Award | 31,250 | $N/A | $0 | |
| Mar 11, 2024 | Marie Eastland Julia | Executive | Disposition | 269,381 | $N/A | $0 | |
| Mar 11, 2024 | J. Lanza Frank | Executive | Disposition | 18,734 | $N/A | $0 | |
| Mar 11, 2024 | R. Robbins Andrew | Executive | Disposition | 5,000 | $N/A | $0 | |
| Mar 11, 2024 | G. Drachman Jonathan | Executive | Disposition | 5,415 | $N/A | $0 | |
| Mar 11, 2024 | Chin Mark | Executive | Disposition | 13,224 | $N/A | $0 | |
| Mar 11, 2024 | Dunseth Myers Scott | Executive | Disposition | 22,665 | $N/A | $0 | |
| Mar 11, 2024 | Nathaniel Walker Luke | Executive | Disposition | 135,000 | $N/A | $0 | |
| Mar 11, 2024 | Hunt Ronald | Executive | Disposition | 10,000 | $N/A | $0 | |
| Mar 11, 2024 | Hunt Ronald | Executive | Disposition | 395,783 | $N/A | $0 | |
| Mar 11, 2024 | Hunt Ronald | Executive | Disposition | 1,463,386 | $N/A | $0 | |
| Mar 11, 2024 | Hunt Ronald | Executive | Disposition | 13,224 | $N/A | $0 | |
| Mar 11, 2024 | P. Silvernail Lauren | Executive | Disposition | 5,000 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 26 | $551.9M | 89.4% |
Sale(S) | 133 | $65.0M | 10.5% |
Exercise(M) | 35 | $492.6K | 0.1% |
Exercise (Options)(X) | 4 | $77.5K | 0.0% |
Payment(F) | 1 | $21.3K | 0.0% |
Disposition(D) | 16 | $0 | 0.0% |
Award(A) | 31 | $0 | 0.0% |
Other(J) | 1 | $0 | 0.0% |
Conversion(C) | 21 | $0 | 0.0% |
Insiders at Harpoon Therapeutics, Inc. are accumulating shares at an accelerated pace. With 32 insiders making 268 transactions totaling $551.9M in purchases versus $65.0M in sales, the net buying activity of $487.0M signals strong executive confidence. &. Co., Inc. Merck (Executive) leads the buying activity with $492.1M in transactions across all time.